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abstract
Background and Aims: in iceland, oncoplastic breast-conservation surgery has been 
performed since 2008. the aim of this population-based study was to assess and compare the 
efficacy and patient satisfaction of standard breast-conservation surgery with oncoplastic 
breast-conservation surgery.
Materials and methods: this is a population-based, retrospective, observational cohort 
study on all women undergoing breast-conservation surgery in iceland from the 1 January 
2008 to 31 december 2014. a multivariate logistic regression and linear regression were 
performed to assess differences in outcomes and a patient satisfaction questionnaire was 
used to assess certain patient-related outcome measures.
Results and conclusion: a total of 750 women underwent breast-conserving surgery, 665 
had standard breast-conservation surgery and 85 oncoplastic breast-conservation surgery. 
Oncoplastic breast-conservation surgery was associated with a significantly larger mean 
size (2.4 cm vs 1.7 cm, p < 0.001) and weight (181.8 g vs 63.4 g, p < 0.001) of breast specimen 
excised when compared to standard breast-conservation surgery. after correcting for 
confounding factors, there was no significant difference in surgical margin involvement 
(odds ratio = 0.97, confidence interval = 0.44–1.97), frequency of complications (odds 
ratio = 1.06, confidence interval = 0.46–2.18), frequency of reoperations (odds ratio = 0.98; 
confidence interval = 0.50–1.81), or time to first adjuvant therapy (–0.23 days for oncoplastic 
breast-conservation surgery, p = 0.95). patient satisfaction was high in both groups, 
although not statistically different (96% in oncoplastic breast-conservation surgery group 
vs 89% in the standard breast-conservation surgery group, p = 0.84). Our results show that 
oncoplastic breast-conservation surgery is at least as safe as standard breast-conservation 
surgery in selected cases and may be preferable in ductal carcinoma in situ.
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BACKgROUnD
For women choosing breast conservation, oncoplas-
tic breast-conservation surgery (OBCS) has emerged 
as a surgical option for many. The goal of this type 
of surgery is to optimize both the oncological and 
cosmetic outcomes of breast conservation. In the 
face of studies suggesting cosmetic failure rates of 
up to 50% following standard breast-conservation 
surgery (SBCS), it seems rational that techniques 
that may potentially improve cosmetic outcomes 
should be offered, especially if they do not compro-
mise on the oncology (1–4).
Previous studies have suggested that cosmetic out-
comes of OBCS may be superior to SBCS (2, 5).
Another potential advantage of OBCS is that it may 
increase the rates of breast-conservation surgery com-
pared to mastectomy, as these techniques allow exci-
sions of larger cancers, which previously would have 
been treated with mastectomy (5, 6).
OBCS can be divided into two different types of 
procedures: volume replacement and volume dis-
placement. With volume replacement, the tumor is 
removed and the defect is replaced with a local flap 
outside of the breast, such as chest wall perforator 
flaps (lateral intercostal artery perforator (LICAP); 
intercostal perforator (ICAP) or pedicled flaps (thora-
codorsal artery perforator (T-DAP) or latissimus 
dorsi ( LD-miniflap). This approach is particularly 
useful in women with smaller, non-ptotic breasts (6–
8). Volume displacement involves either glandular 
rotational flaps or the use of secondary or extended 
dermoglandular flaps within the breast and may 
often involve the use of breast reduction techniques. 
Hence the term therapeutic mammoplasty is often 
used for these types of procedures. These techniques 
are better suited for women with some level of ptosis 
or larger breasts. Contralateral reduction mammo-
plasty is often performed at the same time for breast 
symmetry. Figs 1 and 2 show examples of volume 
replacement and volume displacement.
OBCS has been performed in Iceland since 2008, 
but the extent and efficacy has not been investigated. 
OBCS was offered to women who were at risk of cos-
metic failure with SBCS due to size or location of 
tumor. Also OBCS was rather offered to non-smokers 
and women with larger breasts. The aim of this pop-
ulation-based study was to assess the extent of 
breast-conserving surgery and to compare the effi-
Fig. 1. Volume replacement procedure with a LICAP flap.
Fig. 2. Bilateral volume displacement. On right side, central skin paddle from advanced inferior pedicle.
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cacy and patient satisfaction of SBCS with OBCS 
from 2008 to 2014.
METHODS
STUDy DESIgn
This is a retrospective, observational cohort study on 
all women who underwent breast-conserving surgery 
in Iceland at Landspítali University Hospital from 1 
January 2008 to 31 December 2014. The exclusion cri-
teria were: mastectomy, no tumor seen in the removed 
breast tissue, bilateral SBCS, and males.
The women included in the study were stratified 
in two groups based on whether they underwent 
SBCS or OBCS. The OBCS group contained both vol-
ume displacement (therapeutic mammoplasty) and 
volume replacement procedures. A single surgeon 
(K.S.A.) performed all of the OBCS. Level 1 and level 
2 oncoplastic procedures (minimal gland mobiliza-
tion techniques) were not included in the study 
group.
Data of the patients were collected from medical 
records and included all communication with patient 
from time of diagnosis to end of study period, that is, 
31 December 2014. The data collected were as follows: 
age, smoking status, use of hormone therapy prior to 
diagnosis, positive family history for breast cancer, 
admission time, tumor size, weight of breast tissue 
removed, histological typing, TnM stage, nodal 
involvement, tumor margin status, patients requiring 
re-excision, type of adjuvant therapy, time to first 
adjuvant therapy, and complications (hematomas, ser-
omas, surgical infection, and neurologic pain). The 
data were collected on Excel document.
STATISTICAL AnALySIS
The statistical software R was used for statistical anal-
ysis. T-test and binomial test were used for comparing 
variables in the two stratified groups (i.e. OBCS and 
SBCS).
A number of outcomes were of special interest 
when comparing the efficacy of the two surgical 
approaches, that is, OBCS and SBCS. Those investi-
gated here were rates of tumor involvement in surgi-
cal margins, frequency of complications, time to first 
adjuvant therapy and reoperation rate.
As many of the variables that were sampled are 
dependent on each other, a stepwise backward selec-
tion was applied to see which variables affected the 
outcomes. A multivariate logistic regression and lin-
ear regression were performed to correct for the 
effects of those variables to reveal how the different 
surgical approaches affected the outcomes stated 
above.
A p-value of <0.05 was deemed statistically signifi-
cant.
QUESTIOn LISTS
To evaluate patient satisfaction with aesthetic outcome 
and information provision prior to surgery, question 
lists with six questions were sent out to women in 
both stratification groups.
RESULTS
A total of 750 women underwent breast-conserving 
surgery from 2008 to 2014. Of which, 665 women had 
SBCS as opposed to 85 OBCS. Therefore, 11.3% of all 
patients having breast-conservation surgery in our 
unit had OBCS. Of these 85 patients, 76 (89.4%) had 
volume displacement and 9 (10.6) had volume replace-
ment.
Table 1 summarizes the data collected for the two 
stratified groups.
In Table 1, some significant differences are seen 
between the two stratified groups. Patients in the 
OBCS group were significantly younger and signifi-
cantly fewer were smokers. Also, the mean size tumor 
was significantly larger, nodal involvement was more 
frequent, and more breast tissue was removed in the 
OBCS group. Furthermore, the median admission 
time was significantly longer for the OBCS group, 
although the admission time for OBCS was consider-
ably shorter in the last year of the study period, 2014, 
with a mean of 1.7 days as compared to 3.1 days in the 
first year of the study period, 2008.
Table 2 shows the results of the multivariate logistic 
regression. Linear regression for time to first adjuvant 
therapy showed no statistical difference between the 
OBCS and SBCS (–0.23 days for OBCS with p-value of 
0.95). It is evident that when corrected for the follow-
ing variables: age, smoking status, weight of breast tis-
sue removed, use of hormonal therapy prior to 
surgery, and TnM stage, there is no significant differ-
ence in surgical margin involvement, frequency of 
complications (hematomas, seromas, surgical infec-
tion, and/or neurologic pain), frequency of reopera-
tions, or time to first adjuvant therapy.
DCIS was seen in 57 (7.6%) women who underwent 
breast-conserving surgery (Table 3). Similar percent-
ages of patients had surgery for DCIS in the two 
groups. Although not statistically significant, the rates 
of margin involvement were lower in the OBCS than 
in the SBCS group (42% vs 22%).
Question lists were sent to 448 women in total. Of 
those, 75 were in the OBCS group and 373 in the SBCS 
group. Response rate was 68% in the OBCS group but 
43% in the SBCS group.
Although a detailed patient-related outcome ques-
tionnaire was sent to the patients (Supplementary 
Appendix 1), Fig. 1 shows the patients reply to the 
question whether they were happy with the aesthetic 
outcome of the breast following their surgery.
Fig. 3 shows that overall in both groups there was a 
high satisfaction rate with the cosmetic outcomes of 
the surgery, although a slightly higher rate of women 
in the OBCS group replied with “I agree very much” 
or “I agree for most parts” though the difference is not 
statistically significant.
DISCUSSIOn
In this study, we show that patients offered OBCS in 
our institution, have derived good short-term out-
comes from their surgery, when compared to patients 
having SBCS in the same time period and satisfaction 
with the aesthetic outcome is high. We believe that in 
order to achieve good outcomes for patients having 
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OBCS, a stringent selection criteria needs to be applied, 
especially for breast units beginning to offer these 
types of procedures. In general, they should be offered 
when the expected excision of breast tissue is 
proportionately high and SBCS is likely to result in a 
poor cosmetic outcome (5, 6, 9–11). Also, they should 
be offered when there is a high risk of margin involve-
ment, that is, in multifocal disease or DCIS (12). In the 
UK Sloane project, reoperation rates were nearly twice 
as likely when breast conservation was performed in 
patients with DCIS, irrespective of grade, as compared 
to isolated invasive disease (29.5% vs 18%) (13). 
Studies do in fact suggest that OBCS may reduce reop-
eration rates in patients with DCIS or multifocal dis-
ease (1, 2, 10, 14–16).
In our study, only 11.3% of all women treated with 
breast-conservation surgery had OBCS, which were 
significantly younger, and the large majority (93%), 
were non-smokers when compared to the SBCS 
group. Our results also show that we have selected 
OBCS for women with larger tumors and in situa-
tions where we have deemed larger resection speci-
mens to be preferable, that is, in DCIS (2). Women 
with DCIS and treated with SBCS in this study, had 
over a 40% rate of margin involvement, whereas this 




OR CI OR CI
Tumor at surgical marginsa 1.48 0.80–2.93 0.97 0.44–1.97
Complicationsb 1.01 0.46–2.02 1.06 0.46–2.18
Reoperationsc 1.23 0.64–2.21 0.98 0.50–1.81
CI: confidence interval; OR: odds ratio.
aCorrected for weight of breast tissue.




SBCS (n = 665) OBCS (n = 85) p-value
IDC, n (%) 516 (77.6) 61 (71.8) 0.287
 Positive margins 82 (12.3) 7 (8.2)
 Reoperation 42 (6.3) 7 (8.2)
ILC, n (%) 50 (7.5) 10 (11.8) 0.253
 Positive margins 20 (3.0) 2 (2.4)
 Reoperation 12 (1.8) 1 (1.2)
DCIS, n (%) 48 (7.2) 9 (10.6) 0.375
 Positive margins 20 (41.7) 2 (22.2)
 Reoperation 19 (39.6) 2 (22.2)
OBCS: oncoplastic breast-conservation surgery; SBCS: standard 
breast-conservation surgery; DCIS: ductal carcinoma in situ; IDC: 
invasive ductal carcinoma; ILC: invasive lobular carcinoma.
TABLE 1
Demographic characteristics.
SBCS (n = 665) OBCS (n = 85) p-value
Age. Median (range), years 62.0 (28–94) 50.0 (27–75) <0.001
Size of tumor. Median (range), cm 1.5 (0.1–5.5) 2.0 (0.4–8.0) <0.001
Weight of breast tissue. Median (range), g 51.8 (1.8–660) 126.0 (23.5–1010) <0.001
T and n stages
 T0, n (%) 0 (0) 0(0)  
 T1, n (%) 429 (64.5) 33 (38.8) <0.001
 T2, n (%) 202 (30.3) 43 (50.6) <0.001
 T3, n (%) 35 (5.2) 7 (8.2) 0.383
 n0, n (%) 400 (60.1) 49 (57.6) 0.745
 n1, n (%) 126 (18.9) 20 (23.5) <0.001
 n2, n (%) 13 (2.0) 0 (0) 0.390
 n3, n (%) 9 (1.4) 4 (4.7) 0.073
Smoking, n (%) 152 (22.8) 6 (7.1) <0.05
Hormone therapy, n (%) 141 (21.2) 7 (8.2) <0.05
Admission time. Median (range), days 1 (0.5–17) 2 (1.0–5) <0.001
Positive family history, n (%) 104 (12.9) 11 (15.6) 0.624
DCIS, n (%) 48 (7.2) 9 (10.6) 9.375
Positive margins, n (%) 133 (20.0) 12 (14.3) 0.251
Complications, n (%) 73 (11.0) 11 (12.0) 0.720
Reoperations, n (%) 91 (13.6) 12 (14.1) 1.000
 Hematoma 11 (1.7) 0 (0)
 Extended wedge 21 (3.2) 1 (1.2)
 Mastectomia 52 (7.8) 10 (11.8)
 necrosis 5 (0.8) 0 (0)
 node dissection 2 (0.3) 1 (1.2)
Time between surgery and adjuvant treatment. Median (range), days 50.0 (15–202) 47.5 (22–111) 0.05
OBCS: oncoplastic breast-conservation surgery; SBCS: standard breast-conservation surgery; DCIS: ductal carcinoma in situ.
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Overall, however, in patients with DCIS and invasive 
breast cancer, there did not seem to be a difference in 
margin involvement between the two surgical 
groups.
Therefore, we believe that, at least in the short term, 
OBCS surgery is at least as safe as SBCS, even in larger 
cancers and may be preferable in patients with DCIS. 
This is in agreement with results from previous stud-
ies as mentioned above. To further evaluate the onco-
logical safety of OBCS, such as local recurrence rates, a 
more long-term follow-up is necessary. Recent studies 
with long-term follow-up do however suggest that 
these procedures are oncologically safe. (17)
Because of the higher complexity of OBCS com-
pared to SBCS, concerns have been raised that OBCS 
may be associated with a higher risk of complications, 
which may delay subsequent adjuvant therapy. 
Studies have, however, not supported this view (2, 18, 
19). The results of this study show that complication 
rates following OBCS are not higher when compared 
to SBCS nor is the time to adjuvant therapy prolonged.
When new surgical techniques are being imple-
mented in individual institutions, procedural costs are 
of course of importance. Both the length of operating 
time and hospital stay have bearing when calculating 
these costs. Although in our study, the hospital stay 
for patients having OBCS was on average significantly 
longer than in the SBCS group, the admission time 
shortened considerably from the first year of the study 
period to the last (3.1 days in 2008 vs 1.7 days in 2014).
This highlights the fact that with increasing experi-
ence, the hospital stay may be expected to be equiva-
lent in the two groups. Many experienced breast units 
now offer OBCS as day surgery (2, 20)
Our study is one of the few whole population stud-
ies to publish outcomes on OBCS. A published national 
survey conducted in France showed that OBCS was 
offered to 13.9% of all patients having breast-conserv-
ing surgeries (21). Although the type of OBCS differs 
in this survey in comparison to our study, our study 
shows that proportion of patients being offered OBCS 
was comparable (13.9% vs 11.3%). Overall, it seems 
that the rates of OBCS is relatively low, and one expla-
nation for this is that in the study period, there was 
only one surgeon performing OBCS in our unit. It is 
likely that these rates may increase, if the unit employs 
more oncoplastic breast surgeons in the future.
Regarding the aesthetic outcome, the results of our 
study are in keeping with a recently published study 
that showed good or excellent aesthetic outcome even 
though patients who had OBCS had significantly 
larger tumors and nodal involvement was more fre-
quent (22). The response rate to the question list was 
higher in the OBCS group. It is probably due to closer 
follow-up after the operation when compared to the 
SBCS.
Our study has some limitations. It is retrospective 
and not randomized and thus prone to selection bias. 
For example, there is a certain criteria for choosing 
patient who can have OBCS and thus it was known 
that the two groups would not be identical. We tried to 
correct for those differences with the logistic regres-
sion. The study focuses on short-term outcomes of 
OBCS and thus cannot be used to comment on the 
safety of the OBCS when looking at recurrence rate.
COnCLUSIOn
Our results show that in our unit, OBCS is at least as 
safe as SBCS in selected cases in the short-term. Also, 
patient’s satisfaction with the aesthetic outcomes of 
OBCS is high.
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